Biotech industry leaders urged FDA Director Marty Makary for regulatory stability in a letter citing survey data that shows broad concern over agency predictability; signatories warned that volatility threatens U.S. innovation. The plea coincides with FDA announcements that it is hiring over 1,000 staffers for mission‑critical roles and piloting a program to allow quick email clarifications after sponsor meetings. The agency framed the hires and new communications as ways to speed reviews and reduce uncertainty, while industry groups and CEOs pressed for predictable, science‑driven decisionmaking and transparent policy signals.